This is Archived Content

This content is available for historical purposes only. It may not reflect the current state of science or language from the National Institute on Drug Abuse (NIDA). Find the latest information on substance use, health, and NIDA research at

Cite this article

NIDA. (2013, August 21). NIDA and Lightlake Therapeutics partner to expand access to medication to treat opioid overdose. Retrieved from

press ctrl+c to copy


August 21, 2013

From concept to medication to treatment graphic

NIDA and Lightlake Therapeutics Inc., a biopharmaceutical company developing novel treatments for addictions and conducting clinical trials with intranasal naloxone for the treatment of binge eating disorder, have entered into a partnership to apply this technology towards the treatment of opioid overdose. Clinical trials are expected to begin fall 2013.

Naloxone is an injectable medicine that can rapidly reverse the overdose of prescription and illicit opioids. An intranasal delivery system for naloxone could widely expand its availability and use in preventing opioid overdose deaths, a public health problem of epidemic proportion in the U.S.

For more on the role of naloxone in preventing opioid overdose deaths, see:

To learn more about NIDA’s medications development program, go to:

For more information, contact the NIDA press office at or 301-443-6245.